Clinical trial

Population Based Germline Testing for Early Detection and Prevention of Cancer

NCT07498829

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-12-18

PhaseNA

Study timeline

Study start (actual)2025-12-18Date precision: day

Registry last updated2026-03-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancer Riskunresolved

Ovarian Cancer Riskunresolved

Cancer Gene Mutationunresolved

Interventions

Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer riskGENETIC

Sponsors & collaborators

Queen Mary University of Londonlead sponsor

University of Cambridgecollaborator

University of Manchestercollaborator

London School of Hygiene and Tropical Medicinecollaborator

Institute of Cancer Research, United Kingdomcollaborator

University of Leedscollaborator

Imperial College Londoncollaborator

University College, Londoncollaborator

VU University Medical Center (VUmc)collaborator

St George's, University of Londoncollaborator

Mapped research locations

LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07498829 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.